Miravant SnET2 NDA Filing Target Is Q1 2004; Funds Could Run Out Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Miravant is planning to submit an NDA for its SnET2 PhotoPoint photodynamic therapy for wet age-related macular degeneration in the first quarter of 2004, according to a Nov. 14 quarterly report filed with the Securities & Exchange Commission.